An employee of a Cambridge-based biopharmaceutical company was sentenced yesterday in federal court in Boston for engaging in an insider trading scheme.

Songjiang Wang, 54, of Westford, the director of statistical programming at a Cambridge-based biopharmaceutical company, was sentenced to six months in prison and one year of supervised release. Wang was also ordered to pay a $50,000 fine and scheduled a forfeiture and restitution hearing in the matter for Nov. 30.

A federal jury convicted Wang of one count of conspiracy to commit securities fraud and two count of securities fraud in July.

Co-defendant Schultz “Jason” Chan, 54, of Newton, the director of biostatistics at a different biopharmaceutical company, was convicted of one count of conspiracy to commit securities fraud and three counts of securities fraud. He was sentenced on Nov. 5 to three years in prison and one year of supervised release.

Wang and Chan conspired for almost two years between 2013 and 2015 to commit securities fraud by trading insider information regarding successful clinical drug trials at their respective companies.

Specifically, Wang traded on inside information Chan provided regarding a clinical study conducted by Chan’s employer. In addition, over a period of several months, Wang tipped Chan of clinical trial results for a drug being developed by his employer. Furthermore, Wang gave Chan cash, which Chan used to purchase stock shares of Wang’s employer. Chan subsequently sold those shares and paid back Wang.